Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 27

1.

Inhibition of dengue virus infections in cell cultures and in AG129 mice by a small interfering RNA targeting a highly conserved sequence.

Stein DA, Perry ST, Buck MD, Oehmen CS, Fischer MA, Poore E, Smith JL, Lancaster AM, Hirsch AJ, Slifka MK, Nelson JA, Shresta S, Früh K.

J Virol. 2011 Oct;85(19):10154-66. doi: 10.1128/JVI.05298-11. Epub 2011 Jul 27.

PMID:
21795337
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A mouse model for studying viscerotropic disease caused by yellow fever virus infection.

Meier KC, Gardner CL, Khoretonenko MV, Klimstra WB, Ryman KD.

PLoS Pathog. 2009 Oct;5(10):e1000614. doi: 10.1371/journal.ppat.1000614. Epub 2009 Oct 9.

PMID:
19816561
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A mouse model for studying dengue virus pathogenesis and immune response.

Williams KL, Zompi S, Beatty PR, Harris E.

Ann N Y Acad Sci. 2009 Sep;1171 Suppl 1:E12-23. doi: 10.1111/j.1749-6632.2009.05057.x. Erratum in: Ann N Y Acad Sci. 2009 Oct;1179:234.

PMID:
19751398
[PubMed - indexed for MEDLINE]
4.

Development of a human-murine chimeric immunoglobulin M antibody for use in the serological detection of human flavivirus antibodies.

Thibodeaux BA, Roehrig JT.

Clin Vaccine Immunol. 2009 May;16(5):679-85. doi: 10.1128/CVI.00354-08. Epub 2009 Mar 18.

PMID:
19297614
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Molecular targets for flavivirus drug discovery.

Sampath A, Padmanabhan R.

Antiviral Res. 2009 Jan;81(1):6-15. doi: 10.1016/j.antiviral.2008.08.004. Epub 2008 Sep 15. Review.

PMID:
18796313
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Closing the door on flaviviruses: entry as a target for antiviral drug design.

Perera R, Khaliq M, Kuhn RJ.

Antiviral Res. 2008 Oct;80(1):11-22. doi: 10.1016/j.antiviral.2008.05.004. Epub 2008 Jun 11. Review.

PMID:
18585795
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

E protein domain III determinants of yellow fever virus 17D vaccine strain enhance binding to glycosaminoglycans, impede virus spread, and attenuate virulence.

Lee E, Lobigs M.

J Virol. 2008 Jun;82(12):6024-33. doi: 10.1128/JVI.02509-07. Epub 2008 Apr 9.

PMID:
18400851
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Treatment of yellow fever.

Monath TP.

Antiviral Res. 2008 Apr;78(1):116-24. Epub 2007 Nov 20. Review.

PMID:
18061688
[PubMed - indexed for MEDLINE]
9.

A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs.

Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG.

J Infect Dis. 2007 Mar 1;195(5):665-74. Epub 2007 Jan 23.

PMID:
17262707
[PubMed - indexed for MEDLINE]
Free Article
10.

Neutrophil-activating activity and platelet-activating factor synthesis in cytokine-stimulated endothelial cells: reduced activity in growth-arrested cells.

Takahashi T, Nishizawa Y, Hato F, Shintaku H, Maeda N, Fujiwara N, Inaba M, Kobayashi K, Kitagawa S.

Microvasc Res. 2007 Jan;73(1):29-34. Epub 2006 Oct 5.

PMID:
17027041
[PubMed - indexed for MEDLINE]
11.

Murine model for dengue virus-induced lethal disease with increased vascular permeability.

Shresta S, Sharar KL, Prigozhin DM, Beatty PR, Harris E.

J Virol. 2006 Oct;80(20):10208-17.

PMID:
17005698
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Late vaccination against yellow fever of travelers visiting endemic countries.

Krief I, Goldblatt JG, Paz A, Potasman I.

Travel Med Infect Dis. 2006 Mar;4(2):94-8.

PMID:
16887731
[PubMed - indexed for MEDLINE]
13.

Yellow fever vaccination: how much is enough?

Massad E, Coutinho FA, Burattini MN, Lopez LF, Struchiner CJ.

Vaccine. 2005 Jun 10;23(30):3908-14. Epub 2005 Apr 2.

PMID:
15917112
[PubMed - indexed for MEDLINE]
14.

Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.

Khromava AY, Eidex RB, Weld LH, Kohl KS, Bradshaw RD, Chen RT, Cetron MS; Yellow Fever Vaccine Safety Working Group.

Vaccine. 2005 May 9;23(25):3256-63.

PMID:
15837230
[PubMed - indexed for MEDLINE]
15.

Activation of the cytokine network and unfavorable outcome in patients with yellow fever.

ter Meulen J, Sakho M, Koulemou K, Magassouba N, Bah A, Preiser W, Daffis S, Klewitz C, Bae HG, Niedrig M, Zeller H, Heinzel-Gutenbrunner M, Koivogui L, Kaufmann A.

J Infect Dis. 2004 Nov 15;190(10):1821-7. Epub 2004 Oct 12.

PMID:
15499539
[PubMed - indexed for MEDLINE]
Free Article
16.

Yellow fever: the recurring plague.

Tomori O.

Crit Rev Clin Lab Sci. 2004;41(4):391-427. Review.

PMID:
15487593
[PubMed - indexed for MEDLINE]
17.

Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002.

Cetron MS, Marfin AA, Julian KG, Gubler DJ, Sharp DJ, Barwick RS, Weld LH, Chen R, Clover RD, Deseda-Tous J, Marchessault V, Offit PA, Monath TP.

MMWR Recomm Rep. 2002 Nov 8;51(RR-17):1-11; quiz CE1-4.

PMID:
12437192
[PubMed - indexed for MEDLINE]
Free Article
18.

Yellow fever: an update.

Monath TP.

Lancet Infect Dis. 2001 Aug;1(1):11-20. Review.

PMID:
11871403
[PubMed - indexed for MEDLINE]
19.

Inadequate protection against yellow fever of children visiting endemic areas.

Potasman I, Pick N, Stringer C, Zuckerman JN.

Am J Trop Med Hyg. 2001 Dec;65(6):954-7.

PMID:
11792005
[PubMed - indexed for MEDLINE]
Free Article
20.

Advanced age a risk factor for illness temporally associated with yellow fever vaccination.

Martin M, Weld LH, Tsai TF, Mootrey GT, Chen RT, Niu M, Cetron MS; GeoSentinel Yellow Fever Working Group.

Emerg Infect Dis. 2001 Nov-Dec;7(6):945-51.

PMID:
11747720
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk